ECSP077323A - Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias - Google Patents

Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias

Info

Publication number
ECSP077323A
ECSP077323A EC2007007323A ECSP077323A ECSP077323A EC SP077323 A ECSP077323 A EC SP077323A EC 2007007323 A EC2007007323 A EC 2007007323A EC SP077323 A ECSP077323 A EC SP077323A EC SP077323 A ECSP077323 A EC SP077323A
Authority
EC
Ecuador
Prior art keywords
glucocorticoid receptor
sulfonamide
treatment
inflammatory diseases
receptor modulators
Prior art date
Application number
EC2007007323A
Other languages
English (en)
Inventor
Haakan Bladh
Krister Henriksson
Vijaykumar Hulikal
Matti Lepistoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP077323A publication Critical patent/ECSP077323A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo; composiciones que los comprenden, procedimientos para prepararlos y su uso en terapia médica (por ejemplo modulando el receptor de glucocorticoides en un animal de sangre caliente).
EC2007007323A 2004-10-29 2007-03-14 Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias ECSP077323A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0402635A SE0402635D0 (sv) 2004-10-29 2004-10-29 Chemical compounds

Publications (1)

Publication Number Publication Date
ECSP077323A true ECSP077323A (es) 2007-04-26

Family

ID=33448752

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007323A ECSP077323A (es) 2004-10-29 2007-03-14 Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias

Country Status (21)

Country Link
US (1) US20110130426A1 (es)
EP (1) EP1807405A1 (es)
KR (1) KR20070072550A (es)
CN (1) CN101052627A (es)
AR (1) AR051471A1 (es)
AU (1) AU2005300148A1 (es)
BR (1) BRPI0517259A (es)
CA (1) CA2584409A1 (es)
EC (1) ECSP077323A (es)
GT (1) GT200500306A (es)
IL (1) IL182424A0 (es)
MX (1) MX2007004861A (es)
PA (1) PA8651101A1 (es)
PE (1) PE20060931A1 (es)
RS (1) RS20070077A (es)
RU (1) RU2007115548A (es)
SE (1) SE0402635D0 (es)
TW (1) TW200630352A (es)
UY (1) UY29181A1 (es)
WO (1) WO2006046914A1 (es)
ZA (1) ZA200703389B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800150A (en) 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
MX2010011258A (es) 2008-04-14 2011-06-20 Univ Texas Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
TWI445705B (zh) 2008-05-20 2014-07-21 Astrazeneca Ab 經苯基及苯并二基取代之吲唑衍生物
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
ES2816060T3 (es) 2012-02-29 2021-03-31 Chemocentryx Inc Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
EP2931280B1 (en) 2012-12-14 2018-02-14 Phusis Therapeutics Inc. Methods and compositions for inhibiting cnksr1
MA40592A (fr) 2014-10-06 2016-04-14 Chemocentryx Inc Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
AU2016224930A1 (en) 2015-02-25 2017-09-07 Lupin Limited Process for the preparation of Vortioxetine
WO2016172191A1 (en) 2015-04-20 2016-10-27 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting cnksr1
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
MD4003532T2 (ro) 2019-07-24 2025-01-31 Constellation Pharmaceuticals Inc Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444347A (en) * 1891-01-06 James
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
DE3535167A1 (de) * 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
WO1996036595A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
EP1053227B1 (en) * 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
US6569885B1 (en) * 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7544690B2 (en) * 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
EP1507756B1 (en) * 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
EP2415760A3 (en) * 2003-02-20 2012-02-22 Encysive Pharmaceuticals, Inc. CCR-9 antagonists
EP1643960A2 (en) * 2003-07-02 2006-04-12 Merck & Co., Inc. Arylsulfonamide derivatives
AU2005221140A1 (en) * 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of PPAR (gamma) activity

Also Published As

Publication number Publication date
GT200500306A (es) 2006-06-06
WO2006046914A1 (en) 2006-05-04
US20110130426A1 (en) 2011-06-02
AU2005300148A1 (en) 2006-05-04
CA2584409A1 (en) 2006-05-04
BRPI0517259A (pt) 2008-10-07
MX2007004861A (es) 2007-05-09
AR051471A1 (es) 2007-01-17
PE20060931A1 (es) 2006-10-13
EP1807405A1 (en) 2007-07-18
CN101052627A (zh) 2007-10-10
ZA200703389B (en) 2009-12-30
TW200630352A (en) 2006-09-01
IL182424A0 (en) 2007-07-24
RU2007115548A (ru) 2008-12-10
SE0402635D0 (sv) 2004-10-29
KR20070072550A (ko) 2007-07-04
RS20070077A (sr) 2008-09-29
UY29181A1 (es) 2006-05-31
PA8651101A1 (es) 2006-06-02

Similar Documents

Publication Publication Date Title
ECSP077349A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
UY29875A1 (es) Compuestos quimicos
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
UY30736A1 (es) Compuestos quimicos 537
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
PY2054376A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
ECSP109934A (es) Compuesto - 946
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
ECSP10010693A (es) Compuestos pirazólicos 436
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY30327A1 (es) Nuevos compuestos ii
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
ECSP088296A (es) Compuestos terapéuticos
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY28870A1 (es) Derivados heterocíclicos, composiciones y proceso de preparación
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
PA8720601A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos